Clinical Trial

Adenovirus (RGDCRAdCOX2F)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-15; most recent amendment 2026-01-05.
Status change: Not Yet Recruiting → Recruiting 2024-12-27
Trial Details
NCT Number NCT06693986
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Adenocarcinoma of Pancreas
Enrollment 18 participants
Start Date 2024-12-27
Primary Completion 2028-10-15 (estimated)
Study Completion 2029-10-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-07